Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1042–1048. doi: 10.1038/sj.bjc.6690167

Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia

B Bauvois 1, I De Meester 3, J Dumont 4, D Rouillard 2, H X Zhao 1, E Bosmans 5
PMCID: PMC2362248  PMID: 10098734

Abstract

We have investigated the expression of the ectoenzyme dipeptidylpeptidase IV (DPP IV)/CD26 on lymphocytes obtained from patients with B chronic lymphocytic leukaemia (B-CLL) and compared it with healthy subjects. Using two-colour immunofluorescence analysis with CD26 and CD20 or CD23 monoclonal antibodies, CD26 was found undetectable on peripheral resting B-cells (CD20+ CD23−) from normal donors whereas it was expressed on B-cells activated in vitro with interleukin (IL)-4 and Staphylococcus aureus strain cowan I (CD20+ CD23+). The expression of CD26 on leukaemic B-cells (CD20+ CD23+) was clearly induced in 22 out of 25 patients examined. Consequently, induced levels of CD26 cell surface expression on either normal activated and malignant B-cells coincided with the enhancement of DPP IV activity detected on the surface of these cells. Reverse transcription polymerase chain reaction analyses showed that the transcript levels of the CD26 gene was higher in normal activated B-cells and B-CLL cells than in resting B-cells, suggesting that CD26 was expressed at the level of transcriptional activation. These observations provide evidence of the abnormal expression of DPPIV/CD26 in B-CLL which, therefore, may be considered as a novel marker for B-CLL. Further investigation in relation to CD26 expression and other B malignancies needs to be defined. © 1999 Cancer Research Campaign

Keywords: dipeptidylpeptidase IV, CD26 antigen, B-CLL, B-cell activation

Full Text

The Full Text of this article is available as a PDF (206.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott C. A., Baker E., Sutherland G. R., McCaughan G. W. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 1994;40(5):331–338. doi: 10.1007/BF01246674. [DOI] [PubMed] [Google Scholar]
  2. Andrews C., Crockard A. D., San Miguel J. F., Catovsky D. Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias. Clin Lab Haematol. 1985;7(4):359–368. doi: 10.1111/j.1365-2257.1985.tb00050.x. [DOI] [PubMed] [Google Scholar]
  3. Bauvois B., Sancéau J., Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol. 1992 Apr;22(4):923–930. doi: 10.1002/eji.1830220407. [DOI] [PubMed] [Google Scholar]
  4. Bauvois B., Van Weyenbergh J., Rouillard D., Wietzerbin J. TGF-beta 1-stimulated adhesion of human mononuclear phagocytes to fibronectin and laminin is abolished by IFN-gamma: dependence on alpha 5 beta 1 and beta 2 integrins. Exp Cell Res. 1996 Jan 10;222(1):209–217. doi: 10.1006/excr.1996.0026. [DOI] [PubMed] [Google Scholar]
  5. Carbone A., Cozzi M., Gloghini A., Pinto A. CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to CD30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas. Hum Pathol. 1994 Dec;25(12):1360–1365. doi: 10.1016/0046-8177(94)90098-1. [DOI] [PubMed] [Google Scholar]
  6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  7. Duke-Cohan J. S., Morimoto C., Rocker J. A., Schlossman S. F. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol. 1996 Mar 1;156(5):1714–1721. [PubMed] [Google Scholar]
  8. Eguchi K., Ueki Y., Shimomura C., Otsubo T., Nakao H., Migita K., Kawakami A., Matsunaga M., Tezuka H., Ishikawa N. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. J Immunol. 1989 Jun 15;142(12):4233–4240. [PubMed] [Google Scholar]
  9. Feller A. C., Parwaresch M. R., Lennert K. Subtyping of chronic lymphocytic leukemia of T-type by dipeptidylaminopeptidase IV (DAP IV), monoclonal antibodies, and Fc-receptors. Cancer. 1983 Nov 1;52(9):1609–1612. doi: 10.1002/1097-0142(19831101)52:9<1609::aid-cncr2820520912>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today. 1994 Apr;15(4):180–184. doi: 10.1016/0167-5699(94)90316-6. [DOI] [PubMed] [Google Scholar]
  11. Flentke G. R., Munoz E., Huber B. T., Plaut A. G., Kettner C. A., Bachovchin W. W. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1556–1559. doi: 10.1073/pnas.88.4.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hegen M., Kameoka J., Dong R. P., Schlossman S. F., Morimoto C. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology. 1997 Feb;90(2):257–264. doi: 10.1046/j.1365-2567.1997.00053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Invernizzi R., Bertolino G., Girino M., Perseghin P., Michienzi M., Nano R. Cytochemistry of dipeptidylaminopeptidase IV and II in normal and neoplastic lymphoid cells. Blut. 1985 May;50(5):277–285. doi: 10.1007/BF00319753. [DOI] [PubMed] [Google Scholar]
  14. Jacotot E., Callebaut C., Blanco J., Krust B., Neubert K., Barth A., Hovanessian A. G. Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur J Biochem. 1996 Jul 15;239(2):248–258. doi: 10.1111/j.1432-1033.1996.0248u.x. [DOI] [PubMed] [Google Scholar]
  15. Khalaf M. R., Aqel N. M., Hayhoe F. G. Histochemistry of dipeptidyl aminopeptidase (DAP) II and IV in reactive lymphoid tissues and malignant lymphoma. J Clin Pathol. 1987 May;40(5):480–485. doi: 10.1136/jcp.40.5.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kolb J. P., Genot E., Poggioli J., Abadie A., Sarfati M., Delespesse G., Dugas B. Transduction through CD23: different signalling pathways in human B cells and monocytes. Monogr Allergy. 1991;29:135–155. [PubMed] [Google Scholar]
  17. Kondo S., Kotani T., Tamura K., Aratake Y., Uno H., Tsubouchi H., Inoue S., Niho Y., Ohtaki S. Expression of CD26/dipeptidyl peptidase IV in adult T cell leukemia/lymphoma (ATLL). Leuk Res. 1996 Apr;20(4):357–363. doi: 10.1016/0145-2126(95)00159-x. [DOI] [PubMed] [Google Scholar]
  18. Schön E., Jahn S., Kiessig S. T., Demuth H. U., Neubert K., Barth A., Von Baehr R., Ansorge S. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol. 1987 Dec;17(12):1821–1826. doi: 10.1002/eji.1830171222. [DOI] [PubMed] [Google Scholar]
  19. Scott C. S., Stark A. N., Minowada J., Drexler H. G. Quantitative and qualitative studies of leukaemic cell dipeptidylpeptidases II and IV. Leuk Res. 1988;12(2):129–134. doi: 10.1016/0145-2126(88)90072-0. [DOI] [PubMed] [Google Scholar]
  20. Uematsu T., Urade M., Yamaoka M., Yoshioka W. Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients. J Oral Pathol Med. 1996 Oct;25(9):507–512. doi: 10.1111/j.1600-0714.1996.tb00306.x. [DOI] [PubMed] [Google Scholar]
  21. Yokotani N., Doi K., Wenthold R. J., Wada K. Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. Hum Mol Genet. 1993 Jul;2(7):1037–1039. doi: 10.1093/hmg/2.7.1037. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES